Superworth

Harvard Bioscience price to book ratio HBIO

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
5.1×
10-year median
1.8×
Against its 10-year history
99th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 5.1×
Peer median
1.9×

Harvard Bioscience's price to book ratio is 5.1× as of Oct 23, 2026.

That is above its ten-year median of 1.8×, higher than on 99% of days in the last ten years.

Over that time it ranged from 0.2× in May 2025 to 5.1× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.1×1.4×5.1×
20252.2×0.2×2.4×
20241.3×1.3×2.8×
20233.1×1.5×3.5×
20221.6×1.2×3.5×
20213.7×2.1×4.4×
20202.2×0.7×2.3×
20191.5×0.9×2.1×
20181.4×1.4×3.1×
20171.5×1.1×1.7×
20161.4×0.9×1.6×
20151.2×1.1×2.3×
20141.7×1.2×1.7×
20131.4×1.0×1.5×
20120.9×0.8×1.0×
20110.9×0.9×1.1×

Against its peers

Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.

CompanyPrice to book ratio
HBIOHarvard Bioscience5.1×
NEPHNephros3.2×
ATNMActinium Pharmaceuticals1.6×
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.5×
LFVNLifevantage2.2×
ICCCImmucell3.0×
KEQUKewaunee Scientific1.3×
PDEXPro DEX4.2×
PLXProtalix BioTherapeutics2.9×
NATRNatures Sunshine Products1.3×
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Harvard Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.